Leukemia: A Comprehensive Treatment Guide

Leukemia is a group of blood cancers that originate in the bone marrow, where blood cells are produced. In leukemia, the bone marrow produces large numbers of abnormal white blood cells that do not function properly, crowding out normal blood cells and impairing the body's ability to fight infections, carry oxygen, and control bleeding. The National Cancer Institute estimates approximately 60,000 new cases of leukemia are diagnosed in the United States each year.

Leukemia is broadly classified by how quickly the disease progresses (acute vs. chronic) and by the type of white blood cell affected (lymphoid vs. myeloid), resulting in four main types. Treatment has advanced enormously, with targeted therapies, immunotherapies, and CAR-T cell therapy transforming outcomes for many patients.

Types of Leukemia

Acute Lymphoblastic Leukemia (ALL)

ALL is the most common cancer in children, with peak incidence between ages 2 and 5, though it also occurs in adults (a second peak occurs after age 50). ALL arises from immature lymphoid cells (lymphoblasts) in the bone marrow. It progresses rapidly and requires immediate treatment.

Risk factors include genetic conditions (Down syndrome increases risk 10–20-fold), prior radiation exposure, certain chemical exposures (benzene), and some inherited genetic variants. The Philadelphia chromosome (BCR-ABL fusion gene) is found in approximately 25% of adult ALL and 3–5% of childhood ALL, and has important treatment implications.

Treatment of ALL involves multiple phases:

• Induction therapy — The goal is to achieve complete remission (no detectable leukemia in the bone marrow). Standard regimens include vincristine, corticosteroids (dexamethasone or prednisone), asparaginase, and an anthracycline (daunorubicin). Most patients achieve remission within 4–6 weeks.
• Consolidation (intensification) — High-dose chemotherapy to eliminate residual disease. May include methotrexate, cytarabine, cyclophosphamide, and other agents. Intrathecal chemotherapy is administered to prevent or treat central nervous system involvement.
• Maintenance therapy — Lower-dose oral chemotherapy (typically daily mercaptopurine and weekly methotrexate) for 2–3 years to prevent relapse.
• CNS prophylaxis — Intrathecal chemotherapy (methotrexate with or without cytarabine and hydrocortisone) throughout treatment to prevent leukemia from reaching the brain and spinal cord.

For Philadelphia chromosome-positive ALL, the addition of a tyrosine kinase inhibitor (imatinib or dasatinib) to chemotherapy has dramatically improved outcomes, and many Ph+ ALL patients can now be cured without stem cell transplant. Learn more about chemotherapy.

Acute Myeloid Leukemia (AML)

AML is the most common acute leukemia in adults, with a median age at diagnosis of 68 years. AML arises from myeloid progenitor cells and is a heterogeneous disease with numerous subtypes defined by genetic and molecular abnormalities. These molecular features significantly influence prognosis and treatment selection.

Risk factors include advancing age, prior chemotherapy or radiation (therapy-related AML), exposure to benzene, smoking, myelodysplastic syndromes (MDS), and certain genetic disorders (Down syndrome, Fanconi anemia).

Molecular classification is critical in AML. Key mutations and their significance include:

• FLT3-ITD — Found in approximately 25–30% of AML; associated with higher relapse risk. Treated with FLT3 inhibitors (midostaurin or gilteritinib).
• NPM1 mutation — Found in about 30% of AML; associated with favorable prognosis when FLT3 is not co-mutated.
• IDH1/IDH2 mutations — Found in 15–20% of AML; targeted by ivosidenib (Tibsovo) and enasidenib (Idhifa).
• Core binding factor (CBF) AML — t(8;21) and inv(16) translocations; favorable prognosis with chemotherapy alone.
• Acute promyelocytic leukemia (APL) — Defined by the PML-RARA fusion gene [t(15;17)]. Treated with all-trans retinoic acid (ATRA) and arsenic trioxide, achieving cure rates exceeding 90% without conventional chemotherapy.

Standard AML treatment for fit patients involves:

• Induction: "7+3" regimen (7 days of continuous cytarabine plus 3 days of an anthracycline such as daunorubicin or idarubicin). Midostaurin is added for FLT3-mutated AML. Complete remission rates are approximately 60–80% in younger adults.
• Consolidation: High-dose cytarabine (HiDAC) for favorable-risk patients, or allogeneic stem cell transplant for intermediate- and adverse-risk patients in first remission.

For older or unfit patients who cannot tolerate intensive chemotherapy, lower-intensity options include venetoclax (a BCL-2 inhibitor) combined with a hypomethylating agent (azacitidine or decitabine), which has become a new standard of care with significantly improved outcomes compared to previous low-intensity approaches.

Chronic Lymphocytic Leukemia (CLL)

CLL is the most common leukemia in adults in Western countries, with a median age at diagnosis of 70 years. It involves the accumulation of mature-appearing but functionally incompetent B-lymphocytes in the blood, bone marrow, lymph nodes, and spleen. CLL is often indolent, and many patients do not require treatment for years after diagnosis.

When to treat: CLL treatment is typically initiated when patients develop symptomatic or progressive disease (Rai stage III–IV, rapidly rising lymphocyte count, bulky lymphadenopathy, cytopenias, constitutional symptoms). Asymptomatic early-stage CLL is managed with observation ("watch and wait").

Modern CLL treatment has shifted dramatically away from chemoimmunotherapy toward targeted agents:

• BTK inhibitors — Ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) block Bruton's tyrosine kinase, a critical enzyme for B-cell survival. These oral agents are now the preferred first-line treatment for most CLL patients, with high response rates and durable remissions.
• BCL-2 inhibitors — Venetoclax (Venclexta) induces apoptosis of CLL cells. Typically combined with obinutuzumab (Gazyva) for a fixed-duration (12-month) treatment regimen. This approach offers the advantage of time-limited therapy.
• Chemoimmunotherapy — FCR (fludarabine, cyclophosphamide, rituximab) was the prior standard. Now reserved mainly for younger, fit patients with IGHV-mutated CLL and no high-risk genetic features, where it can be curative in a subset.

Prognostic factors in CLL include del(17p)/TP53 mutation (poor prognosis, responds to BTK and BCL-2 inhibitors but not chemoimmunotherapy), IGHV mutation status (mutated = favorable), and del(11q) (intermediate-poor prognosis).

Chronic Myeloid Leukemia (CML)

CML is defined by the Philadelphia chromosome—a reciprocal translocation between chromosomes 9 and 22, t(9;22), creating the BCR-ABL fusion gene. This gene produces an abnormally active tyrosine kinase that drives the uncontrolled proliferation of myeloid cells. CML accounts for approximately 15% of adult leukemias.

CML has three phases:

• Chronic phase — Most patients (approximately 90%) are diagnosed in chronic phase. The disease is relatively stable and responds well to treatment.
• Accelerated phase — Increasing blast counts and resistance to treatment. Intermediate stage between chronic and blast phases.
• Blast crisis — Resembles acute leukemia (greater than 20% blasts) and is difficult to treat. Can transform into either lymphoid or myeloid blast crisis.

Tyrosine kinase inhibitors (TKIs) are the standard treatment for CML:

• Imatinib (Gleevec) — The first-generation TKI. Achieves complete cytogenetic response in approximately 80–90% of chronic-phase patients.
• Dasatinib (Sprycel) and nilotinib (Tasigna) — Second-generation TKIs that achieve faster and deeper molecular responses. Used first-line or for imatinib-resistant/intolerant patients.
• Bosutinib (Bosulif) — A second-generation TKI approved for newly diagnosed and resistant CML.
• Ponatinib (Iclusig) — A third-generation TKI effective against the T315I gatekeeper mutation that confers resistance to all other TKIs.
• Asciminib (Scemblix) — A first-in-class STAMP inhibitor that targets the ABL myristoyl pocket, working through a different mechanism than other TKIs. Approved for patients who have been treated with two or more prior TKIs.

Treatment-free remission: A remarkable development in CML is the possibility of safely discontinuing TKI therapy in patients who achieve deep molecular response (at least MR4.0) sustained for at least two years. Clinical trials (STIM, EURO-SKI) have shown that approximately 50% of patients who discontinue TKIs maintain treatment-free remission, effectively representing a functional cure. Regular molecular monitoring is essential after discontinuation.

Bone Marrow (Stem Cell) Transplant

Allogeneic hematopoietic stem cell transplant (allo-HSCT) remains an important curative option for certain leukemias. It involves replacing the patient's diseased bone marrow with healthy stem cells from a matched donor. The graft-versus-leukemia (GVL) effect—where the donor's immune cells recognize and attack residual leukemia cells—is a key mechanism of cure.

Allo-HSCT is most commonly used for:

• AML in first remission with intermediate- or adverse-risk genetics
• ALL in first remission with high-risk features (Ph+ ALL, MRD-positive after induction)
• Relapsed or refractory acute leukemias
• CML in accelerated or blast phase, or with TKI resistance

Transplant involves conditioning (high-dose chemotherapy with or without radiation to destroy the diseased marrow), stem cell infusion, and a prolonged recovery period. Major complications include graft-versus-host disease (GVHD), infections, and organ toxicity. Reduced-intensity conditioning regimens have extended transplant eligibility to older patients (up to age 70–75).

CAR-T Cell Therapy

Chimeric antigen receptor T-cell (CAR-T) therapy represents one of the most significant advances in cancer treatment. The patient's own T-cells are collected, genetically engineered in a laboratory to express a receptor targeting a specific protein on leukemia cells (most commonly CD19), expanded to hundreds of millions of cells, and infused back into the patient.

FDA-approved CAR-T products for leukemia include:

• Tisagenlecleucel (Kymriah) — Approved for relapsed or refractory B-cell ALL in patients up to age 25. In the pivotal ELIANA trial, 82% of patients achieved complete remission.
• Brexucabtagene autoleucel (Tecartus) — Approved for relapsed or refractory adult B-cell ALL.

CAR-T therapy can produce dramatic and durable responses in patients who have failed multiple prior therapies. Key side effects include cytokine release syndrome (CRS, a systemic inflammatory response that can range from mild to life-threatening) and immune effector cell-associated neurotoxicity syndrome (ICANS). Both are manageable with tocilizumab, corticosteroids, and supportive care when treated promptly.

Minimal Residual Disease (MRD)

MRD testing uses highly sensitive techniques (flow cytometry, PCR, next-generation sequencing) to detect tiny numbers of remaining leukemia cells that are invisible under a microscope. Achieving MRD-negative status is increasingly recognized as a critical treatment goal across all leukemia types, as it is associated with better long-term outcomes. MRD results are being used to guide treatment decisions, including the need for transplant, duration of therapy, and consideration of additional treatments.

Related Cancer Guides